SG11201810254UA - Blood sample analysis method and system, for determining diabetes - Google Patents

Blood sample analysis method and system, for determining diabetes

Info

Publication number
SG11201810254UA
SG11201810254UA SG11201810254UA SG11201810254UA SG11201810254UA SG 11201810254U A SG11201810254U A SG 11201810254UA SG 11201810254U A SG11201810254U A SG 11201810254UA SG 11201810254U A SG11201810254U A SG 11201810254UA SG 11201810254U A SG11201810254U A SG 11201810254UA
Authority
SG
Singapore
Prior art keywords
blood sample
sample analysis
analysis method
diabetes
diabetes complications
Prior art date
Application number
SG11201810254UA
Inventor
Yoshitaka Isaka
Tomonori Kimura
Keiko Yasuda
Kenji Hamase
Masashi Mita
Original Assignee
Univ Osaka
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka, Shiseido Co Ltd filed Critical Univ Osaka
Publication of SG11201810254UA publication Critical patent/SG11201810254UA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7042—Aging, e.g. cellular aging

Abstract

The purpose of the present invention is to provide: a blood sample analysis method for determining diabetes complications in subjects with kidney damage on the basis of D- and L- amino acid content, from a blood sample; a method for examining diabetes complications; and a 5 sample analysis system that outputs pathological information about diabetes complications. The purpose of this invention is achieved by using at least one amino acid selected from the group consisting of D-aspartic acid, D-proline, L-glutamine, and L-isoleucine, in order to determine diabetes complications. BLOOD SAMPLE ANALYSIS METHOD AND SYSTEM, FOR DETERMINING DIABETES [FIG. 1-A]
SG11201810254UA 2016-05-17 2017-05-17 Blood sample analysis method and system, for determining diabetes SG11201810254UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016099163 2016-05-17
PCT/JP2017/018592 WO2017200025A1 (en) 2016-05-17 2017-05-17 Blood sample analysis method and system, for determining diabetes

Publications (1)

Publication Number Publication Date
SG11201810254UA true SG11201810254UA (en) 2018-12-28

Family

ID=60326004

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810254UA SG11201810254UA (en) 2016-05-17 2017-05-17 Blood sample analysis method and system, for determining diabetes

Country Status (8)

Country Link
US (1) US20190271708A1 (en)
EP (1) EP3460478A4 (en)
JP (2) JP6609282B2 (en)
CN (1) CN109154619A (en)
AU (1) AU2017266331A1 (en)
IL (1) IL263024A (en)
SG (1) SG11201810254UA (en)
WO (1) WO2017200025A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019235591A1 (en) * 2018-06-07 2019-12-12 国立大学法人金沢大学 Disease-state biomarker for kidney disease
CN113196063A (en) * 2018-10-17 2021-07-30 镜株式会社 Marker for renal injury determination in risk stage
CN113631923A (en) * 2019-03-22 2021-11-09 镜株式会社 Method for assisting evaluation of renal condition, renal condition evaluation system, and renal condition evaluation program
US20220252610A1 (en) * 2019-03-22 2022-08-11 Kagami Inc. Method for assisting evaluation of condition of kidneys, system for evaluating condition of kidneys, and program for evaluating condition of kidneys
CN114113349B (en) * 2020-08-26 2024-01-23 湖南农业大学 Method for simultaneously measuring 5 amino acid neurotransmitters in biological matrix based on two-dimensional liquid chromatography-ultraviolet derivatization method
WO2022244842A1 (en) * 2021-05-19 2022-11-24 Kagami株式会社 Composition for regulating carbohydrate metabolism, and method for assessing carbohydrate metabolism conditions of subject

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI351278B (en) * 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
EP1837657A1 (en) * 2006-03-24 2007-09-26 Metanomics GmbH Means and method for predicting or diagnosing diabetes
JP5199994B2 (en) * 2006-03-24 2013-05-15 メタノミクス ゲーエムベーハー Diabetes prediction means and prediction method
US20080026378A1 (en) * 2006-07-28 2008-01-31 Gian Franco Bottazzo Prediction and prophylactic treatment of type 1 diabetes
US20100273661A1 (en) * 2007-06-15 2010-10-28 Smithkline Beecham Corporation Methods and Kits for Predicting Treatment Response in Type II Diabetes Mellitus Patients
EP3067692B1 (en) * 2007-06-29 2019-04-17 Quest Diagnostics Investments Incorporated Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry (lc-ms)
JP5497770B2 (en) * 2009-09-16 2014-05-21 旭化成ファーマ株式会社 A method for distinguishing and predicting atherothrombotic cerebral infarction in acute cerebral infarction
JP2011092100A (en) * 2009-10-29 2011-05-12 Dna Chip Research Inc Gene marker estimating physiological state change and effect of factor giving change in physiological state, estimation method, estimation system and computer program
WO2012164525A2 (en) * 2011-06-01 2012-12-06 Ecole Polytechnique Federale De Lausanne (Epfl) Aging biomarkers
CN107449923B (en) * 2012-03-18 2020-07-24 株式会社资生堂 Disease sample analysis device, disease sample analysis system, and disease sample analysis method
JP6279574B2 (en) * 2012-07-30 2018-02-14 イン オーヴォ ベスローデン フエンノートシャップ Determination of sex, viability and / or developmental stage of avian embryos in eggs
CN102901789A (en) * 2012-09-21 2013-01-30 中国药科大学 Determination method of serum metabolic marker for early diagnosis of diabetic nephropathy.
WO2014120449A1 (en) * 2013-01-31 2014-08-07 Metabolon, Inc. Biomarkers related to insulin resistance progression and methods using the same
EP3842806A1 (en) * 2013-12-11 2021-06-30 Kagami Inc. Marker for early diagnosis of kidney failure
WO2015157407A1 (en) * 2014-04-08 2015-10-15 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment

Also Published As

Publication number Publication date
EP3460478A4 (en) 2020-01-08
WO2017200025A1 (en) 2017-11-23
CN109154619A (en) 2019-01-04
AU2017266331A8 (en) 2018-12-20
IL263024A (en) 2018-12-31
JP6609282B2 (en) 2019-11-20
JP6884346B2 (en) 2021-06-09
JP2019191192A (en) 2019-10-31
EP3460478A1 (en) 2019-03-27
AU2017266331A1 (en) 2018-12-06
JP2017207490A (en) 2017-11-24
US20190271708A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
SG11201810254UA (en) Blood sample analysis method and system, for determining diabetes
EA201891293A1 (en) MULTI-SPECIFIC ANTIBODIES
BR112017004379A2 (en) determination of multi-stage vividness
EA201891292A1 (en) MULTI-SPECIFIC ANTIBODIES
EP3757225A3 (en) Pancreatic cancer detection kit or device, and detection method
EP3816303A3 (en) Breast cancer detection kit or device, and method for detecting breast cancer
WO2016130704A3 (en) Methods and compositions for analyzing cellular components
MX2019003473A (en) Improved methods of assessing uch-l1 status in patient samples.
BR112014016313A8 (en) Accurate analyte measurements for electrochemical test strip based on detected physical characteristic (s) of sample containing analyte and derived biosensor parameters
BR112017018821A2 (en) methods for quantifying insulin levels by mass spectrometry
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
EP3967769A3 (en) Lung cancer detection kit or device, and detection method
MX364886B (en) Ophthalmic lens with a microfluidic system.
PH12015502849A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
CR20190574A (en) Diagnostic assays for detecting, quantifying, and/or tracking microbes and other analytes
EP3508577A3 (en) Modified amadoriase capable of acting on fructosyl hexapeptide
EA201001867A1 (en) CLAMP, INTENDED FOR CAPTURING THE HOLDER OF BIOLOGICAL TESTS, SET OF COMPONENTS, CONSISTING OF THE HOLDER OF BIOLOGICAL TESTS AND RELATED CLAMP, AND A DEVICE FOR TREATMENT OF APPLICATIONS AND PROCESSING FOR THE TREATMENT
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
MX2014006118A (en) Detecting analytes.
SG11201810261UA (en) Kidney disease prognosis prediction method and system
MX2018006189A (en) Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease, or in the diagnosis of parkinson's disease.
WO2011109112A3 (en) Method of detecting tau protein and tau fragments in serum
BR112022008217A2 (en) METHODS AND DEVICES FOR SEQUENCING
WO2010000467A8 (en) Asc as a marker for lung cancer
BR112022012329A2 (en) METHOD TO DETECT A SPECIFIC PROTEIN CONTAINED IN AN EXTRACELLULAR VESICLE, MEMBRANE PERMEABILIZATION TREATMENT AGENT, AND, KIT TO DETECT A SPECIFIC PROTEIN CONTAINED IN AN EXTRACELLULAR VESICLE